Literature DB >> 27435859

Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.

Xiaoli Wu1, Xuefeng Feng2, Xiaoqing Zhao1, Futian Ma1, Na Liu1, Hongming Guo1, Chaonan Li1, Huan Du1, Baoxi Zhang3.   

Abstract

The purpose of the study was to assess the effect of the internal tandem duplication in FMS-like tyrosine kinase 3 (FLT3-ITD) on the outcome in pediatric acute myeloid leukemia (AML) patients. We identified eligible studies from several databases including PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) (from January 1995 to July 2015). Ten studies of 1661 pediatric patients with AML were included in exploring the relationship between the FLT3-ITD and overall survival (OS)/event free survival (EFS). Pediatric patients with AML with FLT3-ITD had worse OS [HR = 2.19 (1.60-3.01)]/EFS [HR = 1.70 (1.37-2.11)] than those patients without FLT3-ITD. Furthermore, FLT3-ITD had unfavorable effect on OS/EFS in the subgroups of NOS, uni/multivariate model, number of patients, the length of following-up, and patient source. The findings of this meta-analysis indicated that FLT3-ITD had negative impact on pediatric patients with AML.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3-ITD; Meta-analysis; Pediatric

Mesh：

Substances：

Year:  2016        PMID： 27435859     DOI： 10.1007/s11010-016-2775-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  30 in total

1.  The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Authors:  Jan-Henning Klusmann; Dirk Reinhardt; Martin Zimmermann; Bernhard Kremens; Josef Vormoor; Michael Dworzak; Ursula Creutzig; Thomas Klingebiel
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Authors:  S Meshinchi; W G Woods; D L Stirewalt; D A Sweetser; J D Buckley; T K Tjoa; I D Bernstein; J P Radich
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

4.  Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.

Authors:  Anna Staffas; Meena Kanduri; Randi Hovland; Richard Rosenquist; Hans Beier Ommen; Jonas Abrahamsson; Erik Forestier; Kirsi Jahnukainen; Ólafur G Jónsson; Bernward Zeller; Josefine Palle; Gudmar Lönnerholm; Henrik Hasle; Lars Palmqvist; Hans Ehrencrona
Journal:  Blood       Date:  2011-10-03       Impact factor: 22.113

5.  [FLT3 mutations in children with acute myeloid leukemia: a single center study].

Authors:  Min Ruan; Ya-Qin Wang; Li Zhang; Tian-Feng Liu; Fang Liu; Xiao-Ming Liu; Jia-Yuan Zhang; Yao Zou; Yu-Mei Chen; Xiao-Fan Zhu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2011-11

Review 6.  Can FLT3 inhibitors overcome resistance in AML?

Authors:  Winnie F Tam; D Gary Gilliland
Journal:  Best Pract Res Clin Haematol       Date:  2008-03       Impact factor: 3.020

7.  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

8.  Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group.

Authors:  Akitoshi Kinoshita; Hayato Miyachi; Hiromichi Matsushita; Miharu Yabe; Tomohiko Taki; Tomoyuki Watanabe; Akiko M Saito; Daisuke Tomizawa; Takashi Taga; Hiroyuki Takahashi; Hidemasa Matsuo; Kumi Kodama; Kentaro Ohki; Yasuhide Hayashi; Akio Tawa; Keizo Horibe; Souichi Adachi
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

9.  The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Authors:  Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279
View more
  8 in total

1.  FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Shanhao Tang; Hongjie Shen; Xinliang Mao; Haiping Dai; Xiaming Zhu; Shengli Xue; Zixuan Ding; Jing Lu; Depei Wu; Xiaowen Tang
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

Review 2.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 3.  High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.

Authors:  Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D'Amico; Giuseppina De Simone; Rosanna Cuccurullo; William G Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro
Journal:  Biomedicines       Date:  2022-06-14

4.  Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group.

Authors:  Alice Marceau-Renaut; Nicolas Duployez; Benoît Ducourneau; Myriam Labopin; Arnaud Petit; Alexandra Rousseau; Sandrine Geffroy; Maxime Bucci; Wendy Cuccuini; Odile Fenneteau; Philippe Ruminy; Brigitte Nelken; Stéphane Ducassou; Virginie Gandemer; Thierry Leblanc; Gérard Michel; Yves Bertrand; André Baruchel; Guy Leverger; Claude Preudhomme; Hélène Lapillonne
Journal:  Hemasphere       Date:  2018-02-21

5.  Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.

Authors:  Daelynn R Buelow; Stanley B Pounds; Yong-Dong Wang; Lei Shi; Yongjin Li; David Finkelstein; Sheila Shurtleff; Geoffrey Neale; Hiroto Inaba; Raul C Ribeiro; Reid Palumbo; Dominique Garrison; Shelley J Orwick; James S Blachly; Karl Kroll; John C Byrd; Tanja A Gruber; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  Clin Transl Sci       Date:  2019-08-20       Impact factor: 4.689

6.  Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era.

Authors:  Sujin Choi; Bo Kyung Kim; Hong Yul Ahn; Kyung Taek Hong; Jung Yoon Choi; Hee Young Shin; Hyoung Jin Kang
Journal:  Blood Res       Date:  2020-12-31

7.  A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia.

Authors:  Nan Zhang; Ying Chen; Shifeng Lou; Yan Shen; Jianchuan Deng
Journal:  Onco Targets Ther       Date:  2019-08-16       Impact factor: 4.147

8.  [Effect of endoplasmic reticulum stress induced by all-trans retinoic acid on apoptosis of FLT3-ITD mutated leukemia cells by activating autophagy in FLT3-ITD mutated protein].

Authors:  L M Zheng; L N Wang; C Liang; C J Peng; W Y Tang; X L Zhang; Y Li; Y L Tang; L B Huang; X Q Luo
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.